Mozobil

— THERAPEUTIC CATEGORIES —
  • Miscellaneous hematological agents
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Mozobil Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Plerixafor 20mg/mL; soln for SC inj; preservative-free.

    Pharmacological Class

    Hematopoietic stem cell mobilizer.

    How Supplied

    Single-dose vial (1.2mL)—1

    Manufacturer

    Sanofi Genzyme Company

    Generic Availability

    NO

    Mechanism of Action

    Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans.

    Mozobil Indications

    Indications

    In combination with granulocyte colony stimulating factor (G-CSF): To mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.

    Mozobil Dosage and Administration

    Adult

    Start after 4 days' treatment with G-CSF. Give by SC inj approx.11hrs before starting apheresis. Repeat up to 4 consecutive days. Base dose on actual body weight. ≤83kg: 20mg fixed dose or 0.24mg/kg once daily; >83kg: 0.24mg/kg once daily. Max 40mg/day. Renal impairment (CrCl≤50mL/min): ≤83kg: 13mg or 0.16mg/kg once daily; >83–<160kg: 0.16mg/kg once daily; max 27mg/day.

    Children

    Not established.

    Mozobil Contraindications

    Not Applicable

    Mozobil Boxed Warnings

    Not Applicable

    Mozobil Warnings/Precautions

    Warnings/Precautions

    Not for use in leukemia. May cause mobilization of tumor cells (in combination with G-CSF). Monitor blood and platelet counts. Monitor for splenic enlargement/rupture after administration in combination with G-CSF; evaluate if left upper abdominal pain and/or scapular or shoulder pain occurs. Monitor for signs of hypersensitivity during and after administration for at least 30mins. Have anaphylactic treatment readily available. Moderate to severe renal impairment. Embryo-fetal toxicity. Advise males and females of reproductive potential to use effective contraception during and for 1 week after the last dose. Pregnancy: avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

    Mozobil Pharmacokinetics

    Distribution

    Apparent volume of distribution: 0.3 L/kg. 

    Elimination

    Renal (~70%). Half-life: 3–5 hours.

    Mozobil Interactions

    Interactions

    May be potentiated by drugs that reduce renal function or compete for active tubular secretion.

    Mozobil Adverse Reactions

    Adverse Reactions

    Diarrhea, nausea, fatigue, inj site reactions, headache, arthralgia, dizziness, vomiting; hypersensitivity reactions (may be serious), tumor cell mobilization, leukocytosis, thrombocytopenia, enlarged spleen, vasovagal reaction may occur.

    Mozobil Clinical Trials

    See Literature

    Mozobil Note

    Not Applicable

    Mozobil Patient Counseling

    See Literature

    Images

    • Latest News Your top articles for Wednesday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More